Chinese companies taken private in the US may consider relisting in Hong Kong as an attractive option, but beware the pitfalls, legal experts involved in the recent WuXi Biologics’ relisting in Hong Kong have warned.
COLIN LAW
WuXi Biologics recently completed its US$510 million global offering and initial public offering (IPO) on the Main Board of the Stock Exchange of Hong Kong, marking the second Chinese company to relist in Hong Kong after going private in the US.
Compared with re-listing in mainland China, one of the major attractions of Hong Kong is the certainty on timing and procedural transparency, Paloma Wang, Hong Kong capital markets partner at Shearman & Sterling, told China Business Law Journal.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
